4,0
14 okt 2024
Huidige werknemer, meer dan 10 jaar
South San Francisco, CA
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Opportunity to learn High level of collaboration Focus on patients
Minpunten
Upward mobility for IC's is and has been the Achille's heel of Genentech. It's glacial. Hyper-focus on AI/ML has come somewhat at the expense of letting the science speak. Everything feels rushed, which doesn't necessarily translate to developing great medicines. Uncharacteristically high amount of layoffs recently, heavily weighted towards IC's. Way too much mid-level management people who contribute little.